Purpose and Summary
H.R. 2004, Tyler's Law, directs the Secretary of Health and
Human Services (HHS) to study the use of fentanyl testing in
hospital emergency departments for patients experiencing an
overdose. The study shall then inform guidance, issued by the
Secretary, on whether hospital emergency departments should
implement fentanyl testing as a routine procedure for patients
experiencing an overdose.
Background and Need for Legislation
Within the last decade, both nonfatal and fatal overdoses
involving fentanyl have increased rapidly.\1\ In 2023 alone,
roughly 69 percent of all drug overdose deaths involved
synthetic opioids other than methadone.\2\ H.R. 2004, Tyler's
Law, is named after Tyler Shamash, a 19-year-old boy who died
of fentanyl poisoning in 2018.\3\ While in the emergency room,
the standard opioid test administered to Tyler did not test for
fentanyl.\4\
---------------------------------------------------------------------------
\1\Ctrs. for Disease Control & Prevention, NCHS Data Brief: No.
522, Drug Overdose Deaths in the United States, 2003-2023 (Dec. 2024),
https://www.cdc.gov/nchs/data/databriefs/db522.pdf.
\2\Ctrs. for Disease Control & Prevention, Fentanyl, Overdose
Prevention (Jun. 2025), https://www.cdc.gov/overdose-prevention/about/
fentanyl.html.
\3\Julie Shamash, Stories: Tyler Shamash, Voices from the Opioid
Crisis (last accessed Sept. 2026), https://
voicesfromtheopioidcrisis.com/tyler-shamash/.
\4\Id.
---------------------------------------------------------------------------
Testing for fentanyl as part of a drug screening panel in
clinical settings is conducted at the hospital's discretion if
there is no testing requirement by the state.\5\ Testing uptake
varies by hospitals, for reasons such as the costs of the
tests, the time required to receive test results, and lack of
standardized clinical guidance.\6\ H.R. 2004 would examine
current fentanyl testing practices, associated costs, as well
as risks and benefits of testing for fentanyl within hospital
emergency departments. These findings would then be utilized to
issue guidance for hospital emergency departments to inform
appropriate implementation of fentanyl testing as a routine
procedure for patients experiencing an overdose.
---------------------------------------------------------------------------
\5\Amanda K. Sarata, Cong. Rsch. Serv. (CRS), IN12219, Clinical
Fentanyl Testing (2023).
\6\Reagan-Udall Foundation for the FDA, Fentanyl Drug Checking and
Screening: Roundtable on Clinical Perspectives Summary Report, (last
accessed Sept. 2026), https://reaganudall.org/sites/default/files/2022-
06/FTS_Clinician%20Roundtable_Final_Complete%206.30.pdf.
---------------------------------------------------------------------------
Committee Action
On March 26, 2026, the Subcommittee on Health held a
hearing on H.R. 2004. The Subcommittee received testimony from:
Scott Oulton, President, INTR3PID Solutions
LLC
K. Fred Gingrich II, DVM, Executive
Director, American Association of Bovine Practitioners
Dennis Lemma, Sheriff, Seminole County,
Florida, and Former President of the Major County
Sheriffs of America
Nabarun Dasgupta, PhD, MPH, Senior Scientist
and Gillings Innovation Fellow, University of North
Carolina at Chapel Hill
Yngvild Olsen, MD, MPH, Former Director of
the Center for Substance Abuse Treatment, Substance
Abuse and Mental Health Services Administration, and
National Advisor, Manatt Health
On June 25, 2026, the Subcommittee on Health met in open
markup session and forwarded H.R. 2004, without amendment, to
the full Committee by a voice vote. On July 21, 2026, the full
Committee on Energy and Commerce met in open markup session and
ordered H.R. 2004, without amendment, favorably reported to the
House by a record vote of 46 yeas and 0 nays.
Committee Votes
Clause 3(b) of rule XIII requires the Committee to list the
record votes on the motion to report legislation and amendments
thereto. The following reflects the record votes taken during
the Committee consideration:
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
OVERSIGHT FINDINGS AND RECOMMENDATIONS
Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of
rule XIII, the Committee held (a) hearing(s) and made findings
that are reflected in this report.
NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY,
AND TAX EXPENDITURES
Pursuant to clause 3(c)(2) of rule XIII, the Committee
finds that H.R. 2004 would result in no new or increased budget
authority, entitlement authority, or tax expenditures or
revenues.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
FEDERAL MANDATES STATEMENT
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
STATEMENT OF GENERAL PERFORMANCE GOALS AND OBJECTIVES
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to direct
the Secretary of HHS to study the use of fentanyl testing in
hospital emergency departments to inform guidance on the
implementation of fentanyl testing as a routine procedure for
patients experiencing an overdose.
DUPLICATION OF FEDERAL PROGRAMS
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 2004 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
RELATED COMMITTEE AND SUBCOMMITTEE HEARINGS
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 2004:
On February 6, 2025, the Subcommittee on
Health held a hearing on H.R. 2004. The title of the
hearing was ``Combatting Existing and Emerging Illicit
Drug Threats.'' The Subcommittee received testimony
from:
Sheriff Michael Bouchard, Vice
President of Government Affairs, Major County
Sheriffs Association;
Mr. Raymond Cullen, Family
Advocate;
Dr. Timothy Westlake, MD, FFSMB,
FACEP, Emergency Medicine Physician, ProHealth
Care Oconomowoc Memorial Hospital;
Ms. Regina LaBelle, JD, Professor
and Director, Master of Science in Addiction
Policy and Practice, Georgetown University
(Minority); and,
Dr. Deepa Camenga, MD, MHS, FAAP,
Chair, Committee on Substance Use and
Prevention, American Academy of Pediatrics
(Minority).
On March 26, 2026, the Subcommittee on
Health held a hearing on H.R. 2004. The title of the
hearing was ``Policies to Protect Our Communities From
Illicit Drug Threats.'' The Subcommittee received
testimony from:
Scott Oulton, President, INTR3PID
Solutions LLC;
K. Fred Gingrich II, DVM,
Executive Director, American Association of
Bovine Practitioners;
Dennis Lemma, Sheriff, Seminole
County, Florida, and Former President of the
Major County Sheriffs of America;
Nabarun Dasgupta, PhD, MPH, Senior
Scientist and Gillings Innovation Fellow,
University of North Carolina at Chapel Hill;
and,
Yngvild Olsen, MD, MPH, Former
Director of the Center for Substance Abuse
Treatment, Substance Abuse and Mental Health
Services Administration, and National Advisor,
Manatt Health.
COMMITTEE COST ESTIMATE
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974.
EARMARK, LIMITED TAX BENEFITS, AND LIMITED TARIFF BENEFITS
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 2004 contains no earmarks, limited
tax benefits, or limited tariff benefits.
ADVISORY COMMITTEE STATEMENT
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
APPLICABILITY TO LEGISLATIVE BRANCH
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
SECTION-BY-SECTION ANALYSIS OF THE LEGISLATION
Section 1. Short title
Section 1 provides a short title of ``Tyler's Law''.
Section 2. Testing for fentanyl in hospital emergency departments
Section 2 directs the Secretary of HHS complete a study
regarding the frequency of hospital emergency department
testing for fentanyl during an overdose, the cost of testing
for fentanyl, the potential benefits and risks with testing for
fentanyl, and the ways in which fentanyl testing in hospital
emergency departments impacts the patient experience.
Following the conclusion of the study, this section directs
the Secretary of HHS issue guidance on the whether hospital
emergency departments should implement fentanyl testing for
patients experiencing an overdose, how hospital emergency
departments can improve clinician awareness of which substances
can be identified by administered drug tests, and how testing
practices could affect the risk of overdose and health
outcomes.
[all]